Antifungal
Treatment Market Information, By Drugs Class (Azoles, Pyrimidines,
Echinocandins, Polyenes, Allylamines, And Others), By Therapeutic Indication
(Systemic, Candidiasis, Coccidioidomycosis, Cryptococcosis, And Prophylactic),
By Pathogen (Candida, Aspergillus, Cryptococcus, Coccidioides Immitis,
Zygomycetes, Trichophyton, And Others), And By End Users (Hospitals &
Clinics, Dermatology Clinics, And Others) - Global Forecast Till 2023
Market Analysis
The global Antifungal
Treatment Market is predicted to touch USD 19,558.0 million at a 4.61% CAGR
over the forecast period (2017-2023), states the latest Market Research Future
(MRFR) report. Fungal infections in the body result from unclean and unhygienic
environments where fungal agents thrive. Such agents grow by spreading spores,
which causes skin infection subsequently or when fungal infections are inhaled
(systematic). Antifungal drugs or treatment are substances that selectively
acts against the fungal pathogen in the fungal infection treatment.
Allylamines, polyenes, echinocandins, pyrimidines, and azoles are the most
widely used antifungal treatments.
Various factors are propelling the antifungal treatment market
growth. Some of these factors, according to the Market Research Future report,
include rising number of patients with fungal diseases, rising geriatric
population, growing awareness regarding different fungal infections, rising
corporate and government initiatives, and rise in population which come in
contact with infections and resistant fungal strains. Additional factors
pushing market growth include the weakened immune system, rising disposable
income, increased investments in research and development activities,
private-public partnership agreements in the pharmaceutical sector to develop
new and effective antifungal drugs, and growing demand for over the counter
(OTC) drugs to treat skin infections.
On the contrary, availability of conventional therapies and
generic drugs for fungal infections, allergic reaction to specific antifungal
drugs, and government regulations in the pharmaceutical industry are factors
that may deter the antifungal treatment market growth over the forecast period.
Market Segmentation
The MRFR report offers a wide segmental analysis of the
antifungal treatment market on the basis of drug class, therapeutic indication,
pathogen, and end users.
Based on drug class, the antifungal treatment market is
segmented into allylamines, polyenes, echinocandins, pyrimidines, azoles, and
others. Of these, the azoles segment will have the largest share in the market
over the forecast period. Azoles are used for treating ocular fungal
infections, systemic candidiasis, blastomycosis, and candidemia.
Based on therapeutic indication, the antifungal treatment market
is segmented into cryptococcosis, coccidioidomycosis, candidiasis, and
systemic. Of these, the systemic segment will dominate the market over the
forecast period.
Based on pathogens, the antifungal treatment market is segmented
into trichophyton, zygomycetes, coccidioides immitis, cryptococcus,
aspergillus, candida, and others.
Based on end user, the antifungal treatment market is segmented
into dermatology clinics, hospitals and clinics, and others.
Browse Complete Report : https://www.marketresearchfuture.com/reports/antifungal-treatment-market-1628
Regional Analysis
By region, the antifungal treatment market report covers the
latest trends and growth opportunities across the Americas, the Asia Pacific,
Europe, and the Middle East and Africa. Of these, the Americas, particularly
North America, will lead the market over the forecast period. This is owing to
the rising incidences of patients in this region with fungal infections,
developed healthcare infrastructure, and quick adoption of new antifungal
treatments.
The antifungal treatment market in Europe will have the
second-largest share in the market over the forecast period. Most companies in
Europe are emphasizing on R&D of antifungal drugs that in turn, is pushing
market growth. These companies are getting government funding that is favoring
the market growth in this region.
The antifungal treatment market in the APAC region is predicted
to grow at the fastest pace over the forecast period. This is owing to the
increasing awareness regarding available fungal infection treatments, rising
healthcare expenditure, rising adoption of new medical practices, and
developing healthcare infrastructure.
The antifungal treatment market in the Middle East and Africa is
predicted to have a slow growth over the forecast period. This is owing to
limited access to healthcare facilities and lack of awareness regarding
antifungal treatments.
Key Players
Leading players profiled in the antifungal treatment market
report include Bayer AG (Germany), Astellas (Japan), Merck & Co., Inc.
(U.S), Sanofi (France), Pfizer Inc. (U.S), and Novartis AG (Switzerland), among
others. Key players have incorporated strategies such as technology launch,
expansion, partnership, collaboration, and acquisition for gaining a
competitive advantage in the market.
March 2019: Pharmbio Korea has signed a deal with BioSynectics
for creating an antifungal treatment, PBK-1819-2. The company will use the
nanotechnology of BioSynectics to create the drug. The nano-conversion
technology will offer an array of perks such as lower side effects, dietary as
well as post-diastolic deviation, and improved bioavailability.
No comments:
Post a Comment